Tamoxifen study aims to unlock breast cancer treatment clues

NCT ID NCT01027416

Completed Knowledge-focused Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed pilot study looked at how the drug tamoxifen affects breast cancer tumors at a molecular level. Researchers studied 59 patients with a specific type of breast cancer to see how tamoxifen changes the interaction between two key proteins. The goal was to gather information that could eventually help doctors choose the right treatment for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tamoxifen
What this could lead to: If successful, this research could help doctors better predict which breast cancer patients will benefit from tamoxifen therapy.
What could go wrong: This is a small, early-stage pilot study with only 59 participants, so results may not apply to all patients. The findings are exploratory and not yet ready to change treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Locations

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
University of Chicago

Chicago, Illinois, 60601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.